Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals announced the hiring of Chief Financial Officer Keith A. Goldan, who received an inducement award to purchase 230,000 shares at an exercise price of $15.60. This stock option will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. The award was approved in compliance with NASDAQ Listing Rule 5635(c)(4). Syndax is focused on developing innovative cancer therapies, including revumenib and axatilimab, which are currently in pivotal trials.
Positive
- Inducement award of 230,000 shares to CFO Keith Goldan may align leadership interests with shareholder value.
- Pipeline includes two therapies, revumenib and axatilimab, currently in pivotal trials, indicating potential future revenue.
Negative
- None.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was +6.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 16, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on June 13, 2022, of Keith A. Goldan as Chief Financial Officer, Mr. Goldan received an inducement award to purchase up to 230,000 shares of common stock. The stock option has an exercise price per share of
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301569831.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.